ArticleParasites & vectors2016
Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
Article in Parasites & vectors, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Cost-effectiveness of vector control for supplementing mass drug administration for eliminating lymphatic filariasis in India.PLoS neglected tropical diseases · 2024Trial
- An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.PLoS neglected tropical diseases · 2021Trial
- COMET-LF: a compartmental model of dynamics of infection, disease, and elimination strategies for lymphatic filariasis.BMC infectious diseases · 2025Article
- Lymphatic filariasis transmission 10 years after stopping mass drug administration in the Gomoa west district of Ghana.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025Article
- Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Lymphatic filariases and soil-transmitted helminthiases in Sri Lanka: the challenge of eliminating residual pockets of transmission.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
- Sensitivity analysis and parameters estimation for the transmission of lymphatic filariasis.Heliyon · 2023Article
- Assessment of antigenemia among children in four hotspots of filarial endemic districts of Nepal during post-MDA surveillance.Tropical medicine and health · 2023Article
- Lymphatic filariasis endgame strategies: Using GEOFIL to model mass drug administration and targeted surveillance and treatment strategies in American Samoa.PLoS neglected tropical diseases · 2023Article
- Optimal Interruption of P. vivax Malaria Transmission Using Mass Drug Administration.Bulletin of mathematical biology · 2023Article
- Global Health Impact: A Model to Alleviate the Burden and Expand Access to Treatment of Neglected Tropical Diseases.The American journal of tropical medicine and hygiene · 2023Article
- A game-theoretic model of lymphatic filariasis prevention.PLoS neglected tropical diseases · 2022Article
- Challenges of using modelling evidence in the visceral leishmaniasis elimination programme in India.PLOS global public health · 2022Article
- Modelling the Impact of Vector Control on Lymphatic Filariasis Programs: Current Approaches and Limitations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Review
- A mathematical model of the dynamics of lymphatic filariasis in Caraga Region, the Philippines.Royal Society open science · 2021Article
- Defining a prevalence level to describe the elimination of Lymphatic Filariasis (LF) transmission and designing monitoring & evaluating (M&E) programmes post the cessation of mass drug administration (MDA).PLoS neglected tropical diseases · 2020Article
- Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis.PLoS neglected tropical diseases · 2020Article
- Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges.PLoS neglected tropical diseases · 2020Article
- Green Micro- and Nanoemulsions for Managing Parasites, Vectors and Pests.Nanomaterials (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndia has made great progress towards the elimination of lymphatic filariasis. By 2015, most endemic districts had completed at least five annual rounds of mass drug administration (MDA). The next challenge is to determine when MDA can be stopped. We performed a simulation study with the individual-based model LYMFASIM to help clarify this.
methodsWe used a model-variant for Indian settings. We considered different hypotheses on detectability of antigenaemia (Ag) in relation to underlying adult worm burden, choosing the most likely hypothesis by comparing the model predicted association between community-level microfilaraemia (Mf) and antigenaemia (Ag) prevalence levels to observed data (collated from literature). Next, we estimated how long MDA must be continued in order to achieve elimination in different transmission settings and what Mf and Ag prevalence may still remain 1 year after the last required MDA round. The robustness of key-outcomes was assessed in a sensitivity analysis.
resultsOur model matched observed data qualitatively well when we assumed an Ag detection rate of 50 % for single worm infections, which increases with the number of adult worms (modelled by relating detection to the presence of female worms). The required duration of annual MDA increased with higher baseline endemicity and lower coverage (varying between 2 and 12 rounds), while the remaining residual infection 1 year after the last required treatment declined with transmission intensity. For low and high transmission settings, the median residual infection levels were 1.0 % and 0.4 % (Mf prevalence in the 5+ population), and 3.5 % and 2.0 % (Ag prevalence in 6-7 year-old children).
conclusionTo achieve elimination in high transmission settings, MDA must be continued longer and infection levels must be reduced to lower levels than in low-endemic communities. Although our simulations were for Indian settings, qualitatively similar patterns are also expected in other areas. This should be taken into account in decision algorithms to define whether MDA can be interrupted. Transmission assessment surveys should ideally be targeted to communities with the highest pre-control transmission levels, to minimize the risk of programme failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.